Trial reportScientific reports2025
Effects of banana blossom supplementation on metabolic parameters in prediabetic adults: a double-blind randomized clinical trial.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Preliminary animal and in vitro studies suggest banana blossoms, a byproduct of banana farming, may help regulate blood sugar and lipid levels and offer antioxidant benefits, though human evidence is limited. This study examined the effects of freeze-dried banana blossom powder (FBP) on fasting blood sugar (FBS), HbA1c, and related health markers in prediabetic Thai adults. In an eight-week double-blind, randomized clinical trial, 42 participants received either 3000 mg/day of FBP or a placebo. Block randomization and third-party blinding ensured unbiased procedures, with similar baseline characteristics across groups. At week eight, measurements included FBS, HbA1c, lipid profile, insulin, liver and kidney function, blood pressure, and anthropometric data. FBP had no significant impact on FBS, HbA1c, lipid profile, or insulin. However, participants in the FBP group showed significant reductions in body weight, BMI, and diastolic blood pressure. Improved bowel movements were also reported, suggesting benefits from FBP’s bioactive compounds. No significant changes in glycemic parameters were detected following FBP supplementation. FBP was well tolerated with no adverse effects, supporting its potential as a functional food for managing weight and blood pressure. The trial was registered at TCTR20240326003.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.